Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
Business Wire•21/10/2026•06:00 ET
0
Key Highlights
- ➤Personalis (PSNL) will present four NeXT Personal ctDNA studies at ESMO 2026
- ➤C-POST Phase 3 data will update survival and ctDNA outcomes in high-risk CSCC
- ➤B-STRONGER-1 will present prospective MRD monitoring data in early-stage triple-negative breast cancer
- ➤Poster studies will assess ctDNA kinetics and biomarkers across advanced and platinum-resistant ovarian cancers
Expert Statements
Richard Chen, President and Chief Medical Officer of Personalis
“B-STRONGER-1 builds on our earlier work in triple-negative breast cancer demonstrating the use of ultrasensitive MRD testing for monitoring neoadjuvant therapy response”
Richard Chen, President and Chief Medical Officer of Personalis
“We are also excited to see NeXT Personal data presented from biopharma in new indications like cutaneous squamous cell carcinoma as we continue to expand evidence around NeXT Personal for a broad range of solid tumors.”
Personalis NeXT Personal(®) Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer
Get started
Create a free account to read the full story.